New drug combo aims to keep deadly blood cancer at bay
NCT ID NCT04062266
Summary
This study is testing whether a two-drug combination (azacitidine and venetoclax) can help keep acute myeloid leukemia (AML) from returning in patients who have achieved remission. The trial will enroll 50 adults with AML who are in remission but are not immediate candidates for a stem cell transplant. The goal is to see if this maintenance therapy can extend the time patients remain cancer-free and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.